Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 3:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Anemia; Sickle-Cell, With Crisis Clear all
Recruiting Not applicable Interventional

Sickle Cell Improvement: Enhancing Care in the Emergency Department

NCT05373771
View directory record Official record
Conditions
Sickle Cell Crisis
Interventions
Care pathway
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 18 Years
Enrollment
5,328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jun 10, 2026, 3:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Microvascular Blood Flow in Sickle Cell Anemia

NCT01566890
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
regadenoson infusion with contrast-enhanced ultrasound, contrast-enhanced ultrasound
Drug · Procedure
Lead sponsor
Versiti Blood Health
Other
Eligibility
18 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Jun 10, 2026, 3:33 PM EDT
Terminated Phase 4 Interventional

Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease

NCT00252122
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Ketamine
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
7 Years to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Jun 10, 2026, 3:33 PM EDT
Completed Not applicable Interventional

Mindfulness and Yoga Therapy for Acute Pain in Sickle Cell Disease

NCT05572294
View directory record Official record
Conditions
Sickle Cell Crisis, Sickle Cell Disease
Interventions
Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Jun 10, 2026, 3:33 PM EDT
Active, not recruiting No phase listed Observational

Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease

NCT05675436
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell Thalassemia, Sickle Cell Pain, Hbss, Hbsc, Sickle Beta Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Syndrome Variant
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
16 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 3:33 PM EDT
Terminated Phase 1Phase 2 Interventional

L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)

NCT04852172
View directory record Official record
Conditions
Acute Vaso Occlusive Crisis (VOC)
Interventions
L-citrulline, D5 1/2NS
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 10, 2026, 3:33 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis

NCT04614610
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Crisis, Pain, Acute
Interventions
Lidocaine Iv, Placebo
Drug
Lead sponsor
Community Medical Center, Toms River, NJ
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Long Branch, New Jersey • New Brunswick, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Jun 10, 2026, 3:33 PM EDT
Completed Phase 3 Interventional

Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)

NCT01737814
View directory record Official record
Conditions
Vaso-occlusive Crisis, Sickle Cell Disease
Interventions
Saline, MST-188
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
4 Years to 65 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
50
States / cities
Mobile, Alabama • Phoenix, Arizona • Oakland, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Jun 10, 2026, 3:33 PM EDT
Terminated Phase 3 Interventional Results available

Apixaban in Patients With Sickle Cell Disease

NCT02179177
View directory record Official record
Conditions
Vaso-occlusive Crisis, Reduction in Hospitalizations, Sickle Cell Disease
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Nirmish Shah
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Jun 10, 2026, 3:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?

NCT03541980
View directory record Official record
Conditions
Sickle Cell Anemia Crisis
Interventions
Acetaminophen, Normal saline
Drug
Lead sponsor
Newark Beth Israel Medical Center
Other
Eligibility
4 Years to 16 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Newark, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Jun 10, 2026, 3:33 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease

NCT01033227
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
sodium nitrite injection, usp
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
8 Years to 23 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Jun 10, 2026, 3:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Blood Flow and Pain Crises in People With Sickle Cell Disease

NCT01568710
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Jun 10, 2026, 3:33 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease

NCT03615924
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Ticagrelor, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 17 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Fort Lauderdale, Florida • Miami, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Jun 10, 2026, 3:33 PM EDT
Terminated Phase 3 Interventional

A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

NCT05348915
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
Inclacumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jun 10, 2026, 3:33 PM EDT
Not yet recruiting Phase 3 Interventional

Optimal Timing of Ketamine Initiation for SCD Pain

NCT07450430
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Crisis
Interventions
Ketamine hydrochloride injection, Placebo
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 24 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jun 10, 2026, 3:33 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

NCT04935879
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Inclacumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jun 10, 2026, 3:33 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

NCT06439082
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Crizanlizumab, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
14
States / cities
Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 10, 2026, 3:33 PM EDT
Completed Phase 3 Interventional

Evaluation of Repeat Administration of Purified Poloxamer 188

NCT02449616
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
MST-188
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
4 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
9
States / cities
San Diego, California • Fort Myers, Florida • Hollywood, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Jun 10, 2026, 3:33 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises

NCT02698761
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Crisis, Vaso-Occlusive Crises
Interventions
Comprehensive Care Plan
Other
Lead sponsor
Valley Anesthesiology Consultants
Other
Eligibility
12 Years to 18 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Jun 10, 2026, 3:33 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease

NCT05456880
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
BEAM-101
Biological
Lead sponsor
Beam Therapeutics Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jun 10, 2026, 3:33 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department

NCT02417298
View directory record Official record
Conditions
Pain, Sickle Cell Disorder
Interventions
Normal saline, Ketamine
Drug
Lead sponsor
Billy Sin
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Jun 10, 2026, 3:33 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

NCT03264989
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
crizanlizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
16 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
12
States / cities
Orange, Florida • Tampa, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jun 10, 2026, 3:33 PM EDT
Completed Phase 1 Interventional

Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease

NCT02989701
View directory record Official record
Conditions
Sickle Cell Disease Without Crisis
Interventions
Plerixafor
Drug
Lead sponsor
Alessandra Biffi
Other
Eligibility
18 Years to 35 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Jun 10, 2026, 3:33 PM EDT
Completed Phase 2 Interventional Results available

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

NCT03474965
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
Crizanlizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Jun 10, 2026, 3:33 PM EDT